Latest oppositions filed by Lindis Biotech Gmbh

This table presents recent patent oppositions filed by Lindis Biotech Gmbh against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsAMGENDec 7, 2017

The following table provides an overview of the latest patents of Lindis Biotech Gmbh that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3177645Feb 17, 2021Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer10